Altimmune
ALT
132 hedge funds and large institutions have $205M invested in Altimmune in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 32 closing their positions.
78% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $14.9M
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
3% more funds holding
Funds holding: 128 → 132 (+4)
7.16% less ownership
Funds ownership: 95.24% → 88.08% (-7.2%)
80% less capital invested
Capital invested by funds: $1.03B → $205M (-$826M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$32.7M |
| 2 |
Millennium Management
New York
|
+$11M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.5M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$8.82M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$7.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$45.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$42.8M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$31.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$21.5M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$17.7M |
ALT Hedge Fund Activity: Q1 2023 in Review
132 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2023, worth a combined $205M — down 80% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ALT positions and 32 closed out — a net gain of 4 holders — while 51 added to existing stakes and 31 trimmed.
The largest buyer was Laurion Capital Management, adding an estimated $32.7M. The largest seller was Janus Henderson Group, cutting an estimated $45.3M.
- 132 institutional investors held Altimmune (ALT) as of Q1 2023, up from 128 in Q4 2022.
- Funds reported $205M of Altimmune stock for Q1 2023, down 80% quarter-over-quarter.
- 36 funds opened new Altimmune positions in Q1 2023 and 32 closed out, a net change of +4 holders.
- The largest Altimmune buyer in Q1 2023 was Laurion Capital Management, an estimated $32.7M added.
- The largest Altimmune seller in Q1 2023 was Janus Henderson Group, an estimated $45.3M sold.
Based on aggregated 13F filings for Q1 2023.